Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01015807 · ClinicalTrials.gov registry record · NA
Transversus Abdominis Plane (TAP) Block for Cesarean Section
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT01015807: Completed NA study, sponsored by University of Washington.
NCT01015807 is a NA study that has completed, run by University of Washington. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01015807, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a transversus abdominis plane (TAP) block with Clonidine added to the injectate (Clo-TAP) performed approximately 2hrs after the cesarean section (CS) will decrease the amount of postoperative hyperalgesia and ultimately reduce post-CS chronic pain.
Primary Outcome
Determine which of three different TAP formulations (Placebo, TAP, Clo-TAP) has the most beneficial effect on the postoperative area of hyperalgesia 48hrs after the start of the cesarean section. The smaller the area of WHA, assessed in cm2, the better the outcome. Area sizes may range from 0 to any size.
Interventions
- DRUG Bupivacaine
- DRUG Clonidine
- DRUG Bupivacaine Placebo
- DRUG Clonidine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT01015807 record still lists
NCT01015807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which Bupivacaine is the first listed.
NCT01015807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01015807 about?
NCT01015807 is a clinical study titled "Transversus Abdominis Plane (TAP) Block for Cesarean Section". The purpose of this study is to determine whether a transversus abdominis plane (TAP) block with Clonidine added to the injectate (Clo-TAP) performed approximately 2hrs after the cesarean section (CS) will decrease the amount of postoperative hyperalgesia and ultimately reduce post-CS chronic pain.
What is the current status of trial NCT01015807?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2009-11. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01015807?
The interventions under investigation include: Bupivacaine (DRUG), Clonidine (DRUG), Bupivacaine Placebo (DRUG), Clonidine Placebo (DRUG).
Who is sponsoring clinical trial NCT01015807?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01015807's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia